A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
NCT ID: NCT06679101
Last Updated: 2026-01-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
520 participants
INTERVENTIONAL
2024-12-16
2031-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM
NCT07150091
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory
NCT05581875
Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
NCT07285239
Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
NCT04808037
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible
NCT05280275
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A: Belantamab Mafodotin + Lenalidomide + Dexamethasone
Belantamab mafodotin, lenalidomide, and dexamethasone will be administered.
Treatment will continue in both arms until progressive disease (PD), death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first.
Belantamab mafodotin
Belantamab mafodotin will be administered.
Lenalidomide
Lenalidomide will be administered.
Dexamethasone
Dexamethasone will be administered.
Arm B: Daratumumab + Lenalidomide + Dexamethasone
Daratumumab, lenalidomide, and dexamethasone will be administered.
Treatment will continue in both arms until PD, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first.
Lenalidomide
Lenalidomide will be administered.
Dexamethasone
Dexamethasone will be administered.
Daratumumab
Daratumumab will be administered.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Belantamab mafodotin
Belantamab mafodotin will be administered.
Lenalidomide
Lenalidomide will be administered.
Dexamethasone
Dexamethasone will be administered.
Daratumumab
Daratumumab will be administered.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form and in the protocol.
3. NDMM with a requirement for treatment as documented per IMWG criteria.
4. Must have at least 1 aspect of measurable disease, as assessed by the central laboratory, defined as 1 of the following:
1. Urine M-protein excretion ≥200 mg/24 hours (≥0.2 g/24 hours) And/or
2. Serum M-protein concentration ≥0.5 g/dL (≥5.0 g/L) And/or
3. Serum free light-chain (FLC) assay: involved FLC level ≥10 mg/dL (≥100 mg/L) and an abnormal serum FLC ratio (\<0.26 or \>1.65).
5. Newly diagnosed and not considered candidate for high-dose chemotherapy with autologous stem cell transplant (ASCT) due to any of the following:
1. ≥70 years of age, OR
2. Age 18 to 69 years with presence of comorbid condition(s) likely to have a negative impact on tolerability of high-dose chemotherapy with ASCT, (or for whom national guidelines do not permit transplant due to a cut-off age below 70 years), OR
3. Who refuse high-dose chemotherapy with ASCT as an initial treatment.
6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
7. Adequate organ system function as defined by the laboratory assessments.
8. Male participants:
* Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
* Male participants are eligible to participate if they agree to the following during the Treatment Period and for at least 6 months after the last dose of study intervention to allow for clearance of any altered sperm:
* Refrain from donating fresh unwashed semen
PLUS either:
* Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent.
OR
* Must agree to use contraception/barrier as detailed below
* Agree to use a male condom, even if they have undergone a successful vasectomy, and female partner to use an additional highly effective contraceptive method with a failure rate of \<1% per year when having sexual intercourse with a woman of childbearing potential (WOCBP) who is not currently pregnant. Male participants should also use a condom when having sexual intercourse with pregnant females.
9. Female participants
* Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
* A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least 1 of the following conditions applies:
* Is not a WOCBP OR
* Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \<1% per year), preferably with low user dependency during the Treatment Period and for 4 months after the last dose of study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention.
* A WOCBP must have 2 negative highly sensitive serum pregnancy tests before starting treatment, the first may be performed within 14 days from C1D1, the second within 24 hours before the first dose of study intervention.
* Should pregnancy occur in a female on treatment or the female partner of a male on treatment, treatment must be stopped, and it is advised to seek advice from a physician specialized or experienced in teratology.
Exclusion Criteria
2. Prior systemic therapy for multiple myeloma, or smoldering multiple myeloma.
3. Signs of meningeal or central nervous system involvement with multiple myeloma.
4. Major surgery within 2 weeks prior to the first dose of study drugs or has not recovered fully from surgery. Kyphoplasty is not considered major surgery.
5. Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions (including lab abnormalities) that could interfere with participant's safety, obtaining informed consent, or compliance with study procedures.
6. Current active liver or biliary disease (except for Gilbert's syndrome or asymptomatic gallstones, or otherwise stable chronic liver disease as per the investigator's assessment).
7. Participants with previous or concurrent malignancies other than multiple myeloma are excluded. Exceptions are any other malignancy that has been considered medically stable for at least 2 years, after discussion with the GSK Medical Monitor. The participant must not be receiving active therapy, other than hormonal therapy for this disease.
8. Evidence of cardiovascular risk including any of the following:
1. Evidence of current clinically significant untreated arrhythmias, including clinically significant electrocardiogram abnormalities including second-degree (Mobitz Type II) or third-degree atrioventricular block.
2. Recent history (within 3 months of screening) of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty or stenting, or bypass grafting.
3. Class III or IV heart failure as defined by the New York Heart Association functional classification system.
9. Known human immunodeficiency virus (HIV) infection, unless the participant can meet all of the following criteria:
1. Established antiretroviral therapy for at least 4 weeks and HIV viral load \<400 copies/mL within Screening Period.
2. CD4+ T-cell (CD4+) counts ≥350 cells/μL.
3. No history of acquired immune deficiency syndrome-defining opportunistic infections within the last 12 months.
10. Positive hepatitis C antibody test result or positive hepatitis C ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study intervention unless the participant can meet the following criteria:
1. RNA test negative.
2. Successful antiviral treatment (usually 8 weeks duration) is required, followed by a negative hepatitis C viral load RNA test after a washout period of at least 4 weeks.
11. Participants with hepatitis B will be excluded unless the defined criteria can be met.
12. Current corneal epithelial disease except for mild punctate keratopathy.
13. Intolerance or contraindications to antiviral prophylaxis.
14. Unable to tolerate antithrombotic prophylaxis.
15. Known immediate or delayed hypersensitivity reaction or idiosyncratic reaction to drugs chemically related to belantamab mafodotin, or any of the components of the study intervention.
16. Plasmapheresis within 7 days prior to the first dose of study intervention.
17. Participants must not have received a live or live-attenuated vaccine within 30 days prior to first dose of belantamab mafodotin.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Mobile, Alabama, United States
GSK Investigational Site
Phoenix, Arizona, United States
GSK Investigational Site
Beverly Hills, California, United States
GSK Investigational Site
Pasadena, California, United States
GSK Investigational Site
Aurora, Colorado, United States
GSK Investigational Site
Englewood, Florida, United States
GSK Investigational Site
Lady Lake, Florida, United States
GSK Investigational Site
Pembroke Pines, Florida, United States
GSK Investigational Site
Saint Augustine, Florida, United States
GSK Investigational Site
Atlanta, Georgia, United States
GSK Investigational Site
Portland, Maine, United States
GSK Investigational Site
Worcester, Massachusetts, United States
GSK Investigational Site
Ann Arbor, Michigan, United States
GSK Investigational Site
Billings, Montana, United States
GSK Investigational Site
Stony Brook, New York, United States
GSK Investigational Site
Charlotte, North Carolina, United States
GSK Investigational Site
Winston-Salem, North Carolina, United States
GSK Investigational Site
Columbus, Ohio, United States
GSK Investigational Site
Providence, Rhode Island, United States
GSK Investigational Site
Austin, Texas, United States
GSK Investigational Site
Kingwood, Texas, United States
GSK Investigational Site
San Antonio, Texas, United States
GSK Investigational Site
Tyler, Texas, United States
GSK Investigational Site
Fairfax, Virginia, United States
GSK Investigational Site
Capital Federal, , Argentina
GSK Investigational Site
Ciudad Autonoma de Buenos Aire, , Argentina
GSK Investigational Site
Córdoba, , Argentina
GSK Investigational Site
Rosario, , Argentina
GSK Investigational Site
Viedma, , Argentina
GSK Investigational Site
Gosford NSW, New South Wales, Australia
GSK Investigational Site
Box Hill, Victoria, Australia
GSK Investigational Site
Melbourne, Victoria, Australia
GSK Investigational Site
Fitzroy, , Australia
GSK Investigational Site
Herston, , Australia
GSK Investigational Site
St Leonards, , Australia
GSK Investigational Site
Bruges, , Belgium
GSK Investigational Site
Brussels, , Belgium
GSK Investigational Site
Ghent, , Belgium
GSK Investigational Site
Hornu, , Belgium
GSK Investigational Site
Roeselare, , Belgium
GSK Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil
GSK Investigational Site
Barretos, , Brazil
GSK Investigational Site
Joinville, , Brazil
GSK Investigational Site
Porto Alegre, , Brazil
GSK Investigational Site
Salvador, , Brazil
GSK Investigational Site
São Paulo, , Brazil
GSK Investigational Site
São Paulo, , Brazil
GSK Investigational Site
São Paulo, , Brazil
GSK Investigational Site
São Paulo, , Brazil
GSK Investigational Site
Teresina, , Brazil
GSK Investigational Site
Vitória, , Brazil
GSK Investigational Site
Saint John, New Brunswick, Canada
GSK Investigational Site
Beijing, , China
GSK Investigational Site
Chengdu, , China
GSK Investigational Site
Chongqing, , China
GSK Investigational Site
Guangzhou, , China
GSK Investigational Site
Guangzhou, , China
GSK Investigational Site
Hangzhou, , China
GSK Investigational Site
Nanchang, , China
GSK Investigational Site
Nanchang, , China
GSK Investigational Site
Nanjing, , China
GSK Investigational Site
Shanghia, , China
GSK Investigational Site
Shenzhen, , China
GSK Investigational Site
Shenzhen, , China
GSK Investigational Site
Tianjin, , China
GSK Investigational Site
Wenzhou, , China
GSK Investigational Site
Xi'an, , China
GSK Investigational Site
Ostrava, , Czechia
GSK Investigational Site
Prague, , Czechia
GSK Investigational Site
Bobigny, , France
GSK Investigational Site
Nantes, , France
GSK Investigational Site
Villejuif, , France
GSK Investigational Site
Jena, Europe, Germany
GSK Investigational Site
Lübeck, Schleswig-Holstein, Germany
GSK Investigational Site
Chemnitz, , Germany
GSK Investigational Site
Cologne, , Germany
GSK Investigational Site
Dresden, , Germany
GSK Investigational Site
Hamburg, , Germany
GSK Investigational Site
Hanover, , Germany
GSK Investigational Site
Mainz, , Germany
GSK Investigational Site
Würzburg, , Germany
GSK Investigational Site
Alexandroupoli, , Greece
GSK Investigational Site
Athens, , Greece
GSK Investigational Site
Athens, , Greece
GSK Investigational Site
Athens, , Greece
GSK Investigational Site
Pátrai, , Greece
GSK Investigational Site
Thessaloniki, , Greece
GSK Investigational Site
Ahmedabad, , India
GSK Investigational Site
Bangalore, , India
GSK Investigational Site
Hyderabad, , India
GSK Investigational Site
Kolkata, , India
GSK Investigational Site
Kolkata, , India
GSK Investigational Site
Pune, , India
GSK Investigational Site
Sushrut Hospital and Research, , India
GSK Investigational Site
Dublin, , Ireland
GSK Investigational Site
Galway, , Ireland
GSK Investigational Site
Waterford, , Ireland
GSK Investigational Site
Beersheba, , Israel
GSK Investigational Site
Jerusalem, , Israel
GSK Investigational Site
Koranit, , Israel
GSK Investigational Site
Petah Tikva, , Israel
GSK Investigational Site
Tel Aviv, , Israel
GSK Investigational Site
Ancona, , Italy
GSK Investigational Site
Catania, , Italy
GSK Investigational Site
Meldola FC, , Italy
GSK Investigational Site
Palermo, , Italy
GSK Investigational Site
Pavia, , Italy
GSK Investigational Site
Pisa, , Italy
GSK Investigational Site
Roma, , Italy
GSK Investigational Site
Shibuya-Ku, Tokyo, Japan
GSK Investigational Site
Aichi, , Japan
GSK Investigational Site
Ehime, , Japan
GSK Investigational Site
Ehime, , Japan
GSK Investigational Site
Fukuoka, , Japan
GSK Investigational Site
Fukushima, , Japan
GSK Investigational Site
Gunma, , Japan
GSK Investigational Site
Hyōgo, , Japan
GSK Investigational Site
Hyōgo, , Japan
GSK Investigational Site
Ibaraki, , Japan
GSK Investigational Site
Ishikawa, , Japan
GSK Investigational Site
Kanagawa, , Japan
GSK Investigational Site
Miyagi, , Japan
GSK Investigational Site
Nara, , Japan
GSK Investigational Site
Numakunai, , Japan
GSK Investigational Site
Osaka, , Japan
GSK Investigational Site
Sapporo, , Japan
GSK Investigational Site
Suita, , Japan
GSK Investigational Site
Tokyo, , Japan
GSK Investigational Site
Yamagata, , Japan
GSK Investigational Site
Bergen, , Norway
GSK Investigational Site
Lrenskog, , Norway
GSK Investigational Site
Oslo, , Norway
GSK Investigational Site
Lodz, , Poland
GSK Investigational Site
Lublin, , Poland
GSK Investigational Site
Lublin, , Poland
GSK Investigational Site
Warsaw, , Poland
GSK Investigational Site
Wałbrzych, , Poland
GSK Investigational Site
Kuils River, , South Africa
GSK Investigational Site
Pretoria, , South Africa
GSK Investigational Site
Hwasun, , South Korea
GSK Investigational Site
Jeonju, , South Korea
GSK Investigational Site
Seoul, , South Korea
GSK Investigational Site
Seoul, , South Korea
GSK Investigational Site
Seoul, , South Korea
GSK Investigational Site
Seoul, , South Korea
GSK Investigational Site
Seoul, , South Korea
GSK Investigational Site
Ulsan, , South Korea
GSK Investigational Site
Badalona, , Spain
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Gijón, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Málaga, , Spain
GSK Investigational Site
Murcia, , Spain
GSK Investigational Site
Salamanca, , Spain
GSK Investigational Site
Santander, , Spain
GSK Investigational Site
Valladolid, , Spain
GSK Investigational Site
Kaohsiung City, , Taiwan
GSK Investigational Site
Taichung, , Taiwan
GSK Investigational Site
Tainan, , Taiwan
GSK Investigational Site
Taipei, , Taiwan
GSK Investigational Site
Taoyuan District, , Taiwan
GSK Investigational Site
Samsun, Atakum, Turkey (Türkiye)
GSK Investigational Site
Kocaeli, İzmit, Turkey (Türkiye)
GSK Investigational Site
Ankara, Yenimahalle, Turkey (Türkiye)
GSK Investigational Site
Adana, , Turkey (Türkiye)
GSK Investigational Site
Ankara, , Turkey (Türkiye)
GSK Investigational Site
Sisli - Istanbul, , Turkey (Türkiye)
GSK Investigational Site
Leicester, , United Kingdom
GSK Investigational Site
Middlesbrough, , United Kingdom
GSK Investigational Site
Oxford, , United Kingdom
GSK Investigational Site
Plymouth, , United Kingdom
GSK Investigational Site
Wolverhampton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-516030-35
Identifier Type: REGISTRY
Identifier Source: secondary_id
214828
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.